QLS 31904
Alternative Names: QLS-31904Latest Information Update: 18 Nov 2022
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Small cell lung cancer
Most Recent Events
- 30 Sep 2022 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (IV) (NCT05461287)
- 20 Jul 2022 Qilu Pharmaceuticals plans a phase I trial for Solid tumours (Late-stage disease) in China (IV) (NCT05461287)
- 08 Apr 2022 QLS 31904 is available for licensing as of 08 Apr 2022. http://en.qilu-pharma.com/intro/7.html